Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers June 27, 2017
Pharmacy Choice - News - Pharmaceutical Industry Trends and Policy - June 27, 2017

Pharmacy News

 Pharmaceutical Industry Trends and Policy
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

6/20/17 - APOLLO HOSPITALS TIES UP WITH CELL THERAPY FIRM
India's largest hospital chain, Apollo Hospitals, entered into an agreement with regenerative medicine company RMS Regrow of Pune to offer cell therapy treatment for bone and cartilage problems. With this, patients suffering from orthopaedic problems like arthritis have a better and painless option over surgeries. Across its hospitals, about 200...
6/20/17 - Global Needle-Free Drug Delivery Market 2017-2021: Endo Pharmaceuticals, Antares Pharma, Inovio Pharmaceuticals, Valeritas, PharmaJet
The market is divided into the following segments based on geography:- Americas- APAC- EMEA. Key vendors- Endo Pharmaceuticals- Antares Pharma- Inovio Pharmaceuticals- Valeritas- PharmaJet. Other prominent vendors- 3 M- Akra Dermojet- Consort Medical- CROSSJECT- Injex Pharma- PenJet Corporation- Zosano- DAntonio Consultants International- European
6/20/17 - Immunicum Announces Publication in Journal for ImmunoTherapy of Cancer of Results Overview from Ilixadencel's First Clinical Study in Metastatic Renal Cell Carcinoma
Press Release 20 June 2017 Immunicum Announces Publication in Journal for ImmunoTherapy of Cancer of Results Overview from Ilixadencel's First Clinical Study in Metastatic Renal Cell Carcinoma Immunicum AB, a biopharmaceutical company advancing a novel immuno-oncology treatment against a range of solid tumors, today announced that the results from.
6/20/17 - Neos Therapeutics Announces FDA Approval of Cotempla XR-ODT? (methylphenidate) Extended-Release Orally Disintegrating Tablets for the Treatment of ADHD in Patients 6 to 17 Years Old
Neos Therapeutics, Inc., a pharmaceutical company focused on developing, manufacturing and commercializing innovative extended-release products using its proprietary modified-release drug delivery and orally disintegrating tablet technologies, today announced that the U.S. Food and Drug Administration approved Cotempla XR-ODT, the first and only.
6/19/17 - "High-Definition Particle Detection during Centrifugation" in Patent Application Approval Process (USPTO 20170153431)
By a News Reporter-Staff News Editor at Pharma Business Week A patent application by the inventors Nguyen, Hoang Thanh; Noolandi, Jaan; Schultheis, Robert James, filed on November 28, 2016, was made available online on June 8, 2017, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent application ha
6/19/17 - (Pr)Xolair added to seven Canadian public drug plans to treat chronic idiopathic urticaria (hives)
-Novartis Pharmaceuticals Canada Inc. is pleased to announce that Canadians in five provinces, the Yukon and those covered under the Non-Insured Health Benefit's Program now have access to Xolair through their public drug plans to treat chronic idiopathic urticaria that is unresponsive to antihistamines. CIU is a skin disease that occurs without
6/19/17 - 15 Stocks Moving In Monday's Pre-Market Session
Chardan Capital upgraded Clovis Oncology from Sell to Neutral. Rice Energy Inc shares rose 27.2 percent to $25.05 in pre-market trading as EQT Corporation announced plans to buy the company for $6.7 billion. Rigel Pharmaceuticals, Inc. rose 14 percent to $2.85 in pre-market trading after the company disclosed that its New Drug Application for TAVAL
6/19/17 - 3M Tegaderm CHG I.V. Securement Dressing Receives FDA 510k Clearance for Expanded Indication to Reduce Catheter-Related Bloodstream Infection
By a News Reporter-Staff News Editor at Clinical Trials Week Catheter-related bloodstream infections are life-threatening for patients and costly for the medical professionals and facilities caring for them. 3 M is pleased to announce that the U.S. Food and Drug Administration has recognized the efficacy of 3 M? Tegaderm? CHG Chlorhexidine Gl
6/19/17 - AbbVie's Upadacitinib ABT-494 Meets All Primary and Ranked Secondary Endpoints in Phase 3 Study in Rheumatoid Arthritis
By a News Reporter-Staff News Editor at Clinical Trials Week AbbVie, a global biopharmaceutical company, announced positive top-line results from the Phase 3 SELECT-NEXT clinical trial evaluating upadacitinib, an investigational oral JAK1-selective inhibitor, in patients with moderate to severe rheumatoid arthritis who did not adequately respond
6/19/17 - Acceleron Pharma Inc. Files SEC Form 8-K, Current Report (Jun. 6, 2017)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Acceleron Pharma Inc. was posted on June 6, 2017. The SEC file number is 0001280600-17-000033.. A U.S. Securities and Exchange Commission filing is a
6/19/17 - Acelrx Pharmaceuticals Inc. Files SEC Form 8-K, Current Report (Jun. 5, 2017)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Acelrx Pharmaceuticals Inc. was posted on June 5, 2017. The SEC file number is 0001437749-17-010591.. A U.S. Securities and Exchange Commission filin
6/19/17 - Acelrx Pharmaceuticals Inc. Files SEC Form S-3, Registration Statement Under Securities Act of 1933 (Jun. 5, 2017)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Acelrx Pharmaceuticals Inc. was posted on June 5, 2017. The SEC file number is 0001437749-17-010647.. A U.S. Securities and Exchange Commission filin
6/19/17 - Acorda Presenting New Tozadenant Data at 2017 MDS Congress
By a News Reporter-Staff News Editor at Pharma Business Week Acorda Therapeutics, Inc. is presenting new data from clinical and preclinical studies of tozadenant at the 2017 International Congress of Parkinson's Disease and Movement Disorders, being held in Vancouver, British Columbia from June 4-8, 2017. "OFF is cited by people with Parkinson's
6/19/17 - Active Pharmaceutical Ingredients/API Industry by Type (chemical/synthetic, biological) and 2027 Forecast
The growing number of contract manufacturers, growing pharmaceutical industry in developing nations, heavy demand for the API products are some of the factors responsible for the growth of active pharmaceutical industry market. Get a sample report at https://www.marketresearchfuture.com/sample-request/1385. Study Objectives Active...
6/19/17 - Adamas Pharmaceuticals Inc. Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities (Jun. 2, 2017)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Adamas Pharmaceuticals Inc. was posted on June 2, 2017. The SEC file number is 0001209191-17-037336.. A U.S. Securities and Exchange Commission filin
6/19/17 - Adamas Pharmaceuticals Inc. Files SEC Form 8-K, Current Report (Jun. 1, 2017)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Adamas Pharmaceuticals Inc. was posted on June 1, 2017. The SEC file number is 0001628280-17-006145.. A U.S. Securities and Exchange Commission filin
6/19/17 - Adamas Pharmaceuticals Inc. Files SEC Form SC 13G, Statement of Acquisition of Beneficial Ownership By Individuals (Jun. 1, 2017)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Adamas Pharmaceuticals Inc. was posted on June 1, 2017. The SEC file number is 0000919574-17-004645.. A U.S. Securities and Exchange Commission filin
6/19/17 - Aerie Pharmaceuticals Inc. Files SEC Form 8-K, Current Report (Jun. 1, 2017)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Aerie Pharmaceuticals Inc. was posted on June 1, 2017. The SEC file number is 0001193125-17-191276.. A U.S. Securities and Exchange Commission filing
6/19/17 - Aerie Pharmaceuticals Inc. Files SEC Form 8-K, Current Report (Jun. 5, 2017)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Aerie Pharmaceuticals Inc. was posted on June 5, 2017. The SEC file number is 0001193125-17-193621.. A U.S. Securities and Exchange Commission filing
6/19/17 - Agency Information Collection Activities; Proposed Collection; Comment Request; Disclosures of Descriptive Presentations in Professional Oncology...
SUMMARY: The Food and Drug Administration is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995, Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information and to allow 60 days for publ
6/19/17 - Agency Information Collection Activities; Proposed Collection; Comment Request; Orphan Drugs; Common European Medicines Agency/Food and Drug...
SUMMARY: The Food and Drug Administration is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995, Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed...
6/19/17 - Agios Pharmaceuticals Inc. Files SEC Form 8-K, Current Report (Jun. 6, 2017)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Agios Pharmaceuticals Inc. was posted on June 6, 2017. The SEC file number is 0001193125-17-195994.. A U.S. Securities and Exchange Commission filing
6/19/17 - Akebia Therapeutics, Inc. Files SEC Form 3, Initial Statement of Beneficial Ownership of Securities (Jun. 1, 2017)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Akebia Therapeutics, Inc. was posted on June 1, 2017. The SEC file number is 0001562180-17-002107.. A U.S. Securities and Exchange Commission filing
6/19/17 - Akebia Therapeutics, Inc. Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities (Jun. 2, 2017)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Akebia Therapeutics, Inc. was posted on June 2, 2017. The SEC file number is 0001562180-17-002141.. A U.S. Securities and Exchange Commission filing
6/19/17 - Aldeyra Therapeutics Announces First Patient Enrolled in Dry Eye Disease Phase 2a Clinical Trial
By a News Reporter-Staff News Editor at Clinical Trials Week Aldeyra Therapeutics, Inc., a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related to aldehydes, announced that it has enrolled the first patient into a Phase 2 a clinical trial of topical ocular ADX-102 for the t
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
RxSchool
Telepharmacy- Remote Delivery of Pharmacy Services
This lesson is supported by:
RxSchool
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415